CY1105979T1 - Νεα οξινα θειικα αλατα πιπepιδινο-2,6-διονων και η χρηση τους για την αντιμετωπιση σχετιζομενων με το στρες συναισθηματικων διαταραχων - Google Patents

Νεα οξινα θειικα αλατα πιπepιδινο-2,6-διονων και η χρηση τους για την αντιμετωπιση σχετιζομενων με το στρες συναισθηματικων διαταραχων

Info

Publication number
CY1105979T1
CY1105979T1 CY20071100144T CY071100144T CY1105979T1 CY 1105979 T1 CY1105979 T1 CY 1105979T1 CY 20071100144 T CY20071100144 T CY 20071100144T CY 071100144 T CY071100144 T CY 071100144T CY 1105979 T1 CY1105979 T1 CY 1105979T1
Authority
CY
Cyprus
Prior art keywords
stress
treatment
novel
dione
pipedino
Prior art date
Application number
CY20071100144T
Other languages
English (en)
Inventor
Maurice Ward Gittos
Original Assignee
Prestwick Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prestwick Pharmaceuticals, Inc. filed Critical Prestwick Pharmaceuticals, Inc.
Publication of CY1105979T1 publication Critical patent/CY1105979T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Νέα όξινα θειικά άλατα ορισμένων 3-φαινυλο-3-διμεθυλαμινοαλκυλο-4,4-διμεθυλοπιπεριδινο-2,6-διονών και φαρμακολογικώς αποδεκτά επιδιαλυτωμένα άλατα αυτών είναι απαλλαγμένα από την απώλεια βάρους και τις ηπατοκυτταρικές μεταβολές στον αρουραίο οι οποίες περιόριζαν σε οριακά αποτελεσματικά επίπεδα τις επιτρεπόμενες κλινικές δόσεις των αντίστοιχων υδροχλωριδίων στην αντιμετώπιση ή προφύλαξη σχετιζόμενων με το στρες συναισθηματικών διαταραχών όπως άγχος, κατάθλιψη, ημικρανία και άπνοια ύπνου. Τα προτιμητέα όξινα θειικά άλατα είναι η όξινη θειική 3(3,5-διμεθοξυφαινυλο)-3-(3-διμεθυλαμινοπροπυλο)-4,4-διμεθυλοπιπεριδινο-2,6-διόνη και, ιδιαίτερα, η όξινη θειική 3(3-μεθοξυφαινυλο)-3-(3-διμεθυλαμινοπροπυλο)-4,4-διμεθυλοπιπεριδινο-2,6-διόνη.
CY20071100144T 2001-08-28 2007-02-01 Νεα οξινα θειικα αλατα πιπepιδινο-2,6-διονων και η χρηση τους για την αντιμετωπιση σχετιζομενων με το στρες συναισθηματικων διαταραχων CY1105979T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0120821A GB2379216A (en) 2001-08-28 2001-08-28 Piperidin-2,6-dione salts useful for the treatment of stress-related affective disorders
PCT/GB2002/003869 WO2003020275A1 (en) 2001-08-28 2002-08-22 Novel piperidin-2,6-dione bisulphate salts and their use for the treatment of stress-related affective disorders

Publications (1)

Publication Number Publication Date
CY1105979T1 true CY1105979T1 (el) 2011-04-06

Family

ID=9921084

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100144T CY1105979T1 (el) 2001-08-28 2007-02-01 Νεα οξινα θειικα αλατα πιπepιδινο-2,6-διονων και η χρηση τους για την αντιμετωπιση σχετιζομενων με το στρες συναισθηματικων διαταραχων

Country Status (19)

Country Link
US (1) US7189742B2 (el)
EP (1) EP1420788B1 (el)
JP (1) JP2005502677A (el)
KR (1) KR100906893B1 (el)
CN (1) CN100506229C (el)
AT (1) ATE347891T1 (el)
AU (1) AU2002321522B2 (el)
BR (1) BR0212175A (el)
CA (1) CA2459009C (el)
CY (1) CY1105979T1 (el)
DE (1) DE60216776T2 (el)
DK (1) DK1420788T3 (el)
ES (1) ES2275898T3 (el)
GB (1) GB2379216A (el)
IL (2) IL160615A0 (el)
MX (1) MXPA04001777A (el)
NZ (1) NZ531345A (el)
PT (1) PT1420788E (el)
WO (1) WO2003020275A1 (el)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0219639D0 (en) * 2002-08-22 2002-10-02 Prestwick Scient Capital Inc Novel piperidin-2,6-dione salts and their use for the treatment of stress-related affective disorders
US7560861B2 (en) 2004-05-03 2009-07-14 Lg Electronics Inc. Organic electro-luminescence display device with an organic electro-luminescence array and fabricating method thereof
MX2007011156A (es) * 2005-03-15 2007-10-23 Hoffmann La Roche Uso de 2-anilino-3,4-dihidro-quinazolinas como antagonistas del receptor 5ht5a.
GB0518763D0 (en) * 2005-09-14 2005-10-19 Prestwick Pharmaceuticals Inc Treatment of hypertension
KR101401612B1 (ko) * 2012-04-30 2014-06-02 재단법인 전남생물산업진흥원 석류 추출물을 유효성분으로 포함하는 스트레스성 질환의 치료 및 예방용 조성물
WO2016033094A1 (en) * 2014-08-25 2016-03-03 Aimmune Therapeutics, Inc. Egg protein formulations and methods of manufacture thereof
WO2017087691A1 (en) 2015-11-17 2017-05-26 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms
WO2019094596A1 (en) 2017-11-09 2019-05-16 The Trustees Of Columbia University In The City Of New York Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3693729A (en) * 1970-02-19 1972-09-26 Global Marine Inc Air cushion drilling vehicle
GB1455687A (en) * 1972-12-28 1976-11-17 Aspro Nicholas Ltd Pharmacologically active 3-phenyl-3-aminoalkyl-2,6-dioxo-hydro genated pyridines
DE3686622T2 (de) * 1985-09-11 1993-04-01 British Tech Group Verwendung von dioxopiperidin-derivaten zur behandlung von anxietas, zur herabsetzung von chronischen abnormal hohen gehirn-spiegeln serotonins oder 5-hydroxy-indolessigsaeure und zur behandlung von bakteriellen oder viralen infektionen.
EP0263594B1 (en) * 1986-09-08 1992-06-24 Btg International Limited Anxiolytic compositions containing dioxopiperidine derivatives
US5104990A (en) * 1990-02-27 1992-04-14 G. D. Searle & Co. Process for the preparation of 3-aryl-3-aminoalkyl-2,6-dioxohexahydropyridines

Also Published As

Publication number Publication date
KR100906893B1 (ko) 2009-07-08
GB0120821D0 (en) 2001-10-17
BR0212175A (pt) 2004-07-20
CN100506229C (zh) 2009-07-01
PT1420788E (pt) 2007-03-30
EP1420788A1 (en) 2004-05-26
KR20040031000A (ko) 2004-04-09
DK1420788T3 (da) 2007-02-26
IL160615A0 (en) 2004-07-25
US7189742B2 (en) 2007-03-13
NZ531345A (en) 2005-07-29
DE60216776D1 (de) 2007-01-25
US20040249159A1 (en) 2004-12-09
WO2003020275A1 (en) 2003-03-13
CA2459009C (en) 2010-04-06
CN1549715A (zh) 2004-11-24
GB2379216A (en) 2003-03-05
EP1420788B1 (en) 2006-12-13
ES2275898T3 (es) 2007-06-16
JP2005502677A (ja) 2005-01-27
AU2002321522B2 (en) 2006-10-12
ATE347891T1 (de) 2007-01-15
IL160615A (en) 2008-08-07
DE60216776T2 (de) 2007-10-04
CA2459009A1 (en) 2003-03-13
MXPA04001777A (es) 2004-11-22

Similar Documents

Publication Publication Date Title
CY1105979T1 (el) Νεα οξινα θειικα αλατα πιπepιδινο-2,6-διονων και η χρηση τους για την αντιμετωπιση σχετιζομενων με το στρες συναισθηματικων διαταραχων
CY1105541T1 (el) Παμοϊκα αλατα πιπεριδινο-2,6-διονων και η χρηση τους για την αντιμετωπιση σχετιζομενων με το στρες συναισθηματικων διαταραχων
CY1110472T1 (el) Αναλογα λιποξινης α4
CY1105907T1 (el) Νεα παραγωγα της 1,2,4 - θειαδιαζολης ως ρυθμιστες υποδοχεως μελανοκορτινης
CY1120250T1 (el) Ετεροκυκλικες αρωματικες ενωσεις χρησιμες ως εκκριταγωγα αυξητικης ορμονης
DE602005025988D1 (de) Zwischenprodukte für die herstellung von pramipexol
CY1106894T1 (el) Παραγωγα σουλφοναμιδιων για την αγωγη ασθενειων
CY1113194T1 (el) Συνθεση και αντιϊικη δραστικοτητα παραγωγων υποκατεστημενης αζαϊνδολοοξοοξικης πιπεραζινης
DK1392287T3 (da) Anvendelse af substituerede azetidinonderivater i behandlingen af Alzheimers sygdom
CY1110735T1 (el) 3- ή 4-μονοϋποκατασταθεντα παραγωγα φαινολης και θειοφαινολης χρησιμα ως προσδεματα η3
CY1114582T1 (el) Παραγωγα αλκυνυλιου ως ρυθμιστες μεταβολοτροπων υποδοχεων γλουταμινικου οξεος
BR0116464A (pt) imidazoquinolinas substituìdas com amido éter
NO20062303L (no) Pyrazinderivater og farmasoytisk anvendelse derav
DE60325693D1 (de) Inaktivierung des west nile virus und plasmodium falciparum durch die verwendung von alloxazin-derivaten von photosensitizers
ATE529415T1 (de) Nitrosubstituierte phenylpiperazinverbindungen, deren herstellung und deren verwendung in medikamenten
ATE347555T1 (de) 6-aminomorphinanderivate, herstellungsverfahren dafür und deren verwendung
NO20035116D0 (no) 4-(fenylpiperidin-4-yliden-metyl)-benzamidderivater og deres anvendelse forbehandling av smerte, angst eller gastrointestinale forstyrrelser
NO20054721L (no) Substituerte anilinderivater
NO20035115D0 (no) 4-(fenylpiperidin-4-yliden-metyl)-benzamidderivater og deres anvendelse forbehandling av smerte, angst eller gastrointestinale forstyrrelser
NO20035117D0 (no) 4-(fenylpiperidin-4-yliden-metyl)-benzamidderivater og deres anvendelse forbehandling av smerte, angst eller gastrointestinale forstyrrelser
ITMI20032172A1 (it) Procedimento atto alla correzione dell'arricchimento di
DK1471916T3 (da) Behandling af rheumatoid arthritis under anvendelse af imatinib
NO20035118D0 (no) 4-(fenylpiperidin-4-yliden-metyl)-benzamidderivater og deres anvendelse forbehandling av smerte, angst eller gastrointestinale forstyrrelser
EE200300535A (et) 4-(fenüül(piperidiin-4-üül)amino)bensamiidi derivaadid ja nende kasutamine valu, ärevuse või seedetrakti häirete raviks
PE20050230A1 (es) Derivados de 2 aminobenzoilo